The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors.
Abstract Details
Viral hepatitis in 2021: The challenges remaining and how we should tackle them
World J Gastroenterol. 2022 Jan 7;28(1):76-95. doi: 10.3748/wjg.v28.i1.76.
Rebecca Dunn1, Aaron Wetten2, Stuart McPherson2, Mhairi C Donnelly3
Author information
1Gastroenterology, University Hospital of North Tees, Stockton on Tees TS198PE, United Kingdom.
2Liver Unit, Freeman Hospital, Newcastle NE77DN, United Kingdom.
3Liver Unit, Freeman Hospital, Newcastle NE77DN, United Kingdom. mhairi.donnelly@nhs.net.
Abstract
Viral hepatitis results in 1.4 million deaths annually. The World Health Organization (WHO) set an ambitious target to eliminate viral hepatitis by 2030, but significant challenges remain. These include inequalities in access to healthcare, reaching at risk populations and providing access to screening and effective treatment. Stigma around viral hepatitis persists and must be addressed. The WHO goal of global elimination by 2030 is a worthy aim, but remains ambitious and the coronavirus 2019 pandemic undoubtedly has set back progress. This review article will focus on hepatitis A to E, highlighting problems that have been resolved in the field over the past decade, those that remain to be resolved and suggest directions for future problem solving and research.
Stay Informed!
